Latest News and Press Releases

                            AC Immune to receive third milestone payment of CHF 14 million under collaboration agreement with Genentech Phase 2 to evaluate effects of anti-Tau antibody in...

AC Immune to Present at Two Investor Conferences and Provide Scientific Updates at CTAD Conference Lausanne, Switzerland, - October 24, 2017 -   AC Immune SA (NASDAQ: ACIU), a Swiss-based,...

Continued development of PET tracer for earlier and more accurate diagnosis of Parkinson's disease Focuses on alpha-synuclein, a key protein in Parkinson's disease pathology Lausanne,...

AC Immune completes Recruitment for Low-Dose Cohort of Participants in World's First Clinical Trial for anti-Abeta Vaccine Targeting Alzheimer's Disease-like Characteristics in Individuals with Down...

Pipeline expansion with new antibodies against alpha-synuclein and TDP-43 Proprietary scientific approach rapidly delivers high-quality assets Execution of clear strategy around three pillars ...

Strong cash position of CHF 124.2 million provides resources to advance pipeline of seven therapeutic and three diagnostic candidates Increased R&D investment across three pillars of...

Lausanne, Switzerland, July 10, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that seven updates...

Lausanne, Switzerland, June 28, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the...

Powerful synergies in technologies and expertise Provides AC Immune with first R&D collaboration in Asia              Lausanne, Switzerland, Hong Kong, China, May 22, 2017 - AC Immune...

Strong cash position of CHF 138.1 million provides resources to advance pipeline of seven therapeutic and three diagnostic candidates Second pivotal Phase 3 clinical trial of crenezumab -...